Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Novo Nordisk A/S
Age
18–74
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Informed consent obtained before any trial-related activities.
Type 1 or type 2 diabetes
Daily injection(s) with anti-diabetic drug (insulin or Glucagon like Peptide-1 (GLP-1) analogues) via pen-injector or vial/syringe for more than 6 months
Body mass index (BMI) between 18.5 and 30.0 kg/m\^2 (both included)
Caucasians
You may not be if
Known or suspected hypersensitivity to needle, ink ball pen or other that are in contact with the injection area during the clinical visit
Previous participation in this trial. Participation is defined as: screened
Receipt of any investigational medicinal product that can influence pain perception within 14 days before screening
Injection of more than 40 units of insulin per injection
Continuous Subcutaneous Insulin Infusion use within the last 6 months
Continuous Glucose Monitoring use within the last 6 months
Intake of any pain-relieving or analgesic within the last week (excluding low dose aspirin in cardio vascular prophylactic doses)
Known active or in-active skin disease in the injection area or that may affect pain perception
Anti-coagulant treatment within the last month (low dose of aspirin in cardiovascular prophylactic doses is allowed. However, not on the day of the injections)
